NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Overwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanisms remain largely speculative. It is, however, likely that common mechanisms contribute to the development of CVD and NAFLD, with lifestyle fa...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/3/467 |
| _version_ | 1797407272906784768 |
|---|---|
| author | David Niederseer Bernhard Wernly Elmar Aigner Felix Stickel Christian Datz |
| author_facet | David Niederseer Bernhard Wernly Elmar Aigner Felix Stickel Christian Datz |
| author_sort | David Niederseer |
| collection | DOAJ |
| description | Overwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanisms remain largely speculative. It is, however, likely that common mechanisms contribute to the development of CVD and NAFLD, with lifestyle factors such as smoking, sedentary lifestyle with poor nutrition habits and physical inactivity being major candidates. These behavioral factors, on a predisposing genetic background, trigger changes in gut microbiota, inflammation, dyslipidemia and oxidative stress, leading to metabolic syndrome, diabetes and obesity as well as atherosclerosis. Treatment options to counteract both the progression and development of CVD and NAFLD include lifestyle interventions, optimal medical therapy of comorbid conditions and, as final possibility, bariatric surgery. As no causal pharmacotherapy of NAFLD is available, further research is urgently needed to address the unmet need of a growing population with NAFLD and CVD. |
| first_indexed | 2024-03-09T03:38:53Z |
| format | Article |
| id | doaj.art-e2245fa124de436f861d16616227e292 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T03:38:53Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-e2245fa124de436f861d16616227e2922023-12-03T14:44:19ZengMDPI AGJournal of Clinical Medicine2077-03832021-01-0110346710.3390/jcm10030467NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic ConsiderationsDavid Niederseer0Bernhard Wernly1Elmar Aigner2Felix Stickel3Christian Datz4Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, University of Zurich, 8091 Zurich, SwitzerlandDepartment of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University Salzburg, 5020 Salzburg, AustriaFirst Department of Medicine, Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Gastroenterology, University Hospital Zurich, University of Zurich, 8091 Zurich, SwitzerlandDepartment of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University, 5110 Oberndorf, AustriaOverwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanisms remain largely speculative. It is, however, likely that common mechanisms contribute to the development of CVD and NAFLD, with lifestyle factors such as smoking, sedentary lifestyle with poor nutrition habits and physical inactivity being major candidates. These behavioral factors, on a predisposing genetic background, trigger changes in gut microbiota, inflammation, dyslipidemia and oxidative stress, leading to metabolic syndrome, diabetes and obesity as well as atherosclerosis. Treatment options to counteract both the progression and development of CVD and NAFLD include lifestyle interventions, optimal medical therapy of comorbid conditions and, as final possibility, bariatric surgery. As no causal pharmacotherapy of NAFLD is available, further research is urgently needed to address the unmet need of a growing population with NAFLD and CVD.https://www.mdpi.com/2077-0383/10/3/467diabetesmetabolic syndromelifestyleatherosclerosisNASHliver |
| spellingShingle | David Niederseer Bernhard Wernly Elmar Aigner Felix Stickel Christian Datz NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations Journal of Clinical Medicine diabetes metabolic syndrome lifestyle atherosclerosis NASH liver |
| title | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations |
| title_full | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations |
| title_fullStr | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations |
| title_full_unstemmed | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations |
| title_short | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations |
| title_sort | nafld and cardiovascular diseases epidemiological mechanistic and therapeutic considerations |
| topic | diabetes metabolic syndrome lifestyle atherosclerosis NASH liver |
| url | https://www.mdpi.com/2077-0383/10/3/467 |
| work_keys_str_mv | AT davidniederseer nafldandcardiovasculardiseasesepidemiologicalmechanisticandtherapeuticconsiderations AT bernhardwernly nafldandcardiovasculardiseasesepidemiologicalmechanisticandtherapeuticconsiderations AT elmaraigner nafldandcardiovasculardiseasesepidemiologicalmechanisticandtherapeuticconsiderations AT felixstickel nafldandcardiovasculardiseasesepidemiologicalmechanisticandtherapeuticconsiderations AT christiandatz nafldandcardiovasculardiseasesepidemiologicalmechanisticandtherapeuticconsiderations |